April 2007 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

April 2007

Pharmaceutical Technology


BIO Raises Concerns About Studies on Follow-On Biologics

Washington, DC (Feb. 22)—The Biotechnology Industry Organization (BIO, Washington, DC, http://www.bio.org/) criticized two separate studies respectively released by the Pharmaceutical Care Management Association (PCMA, Washington, DC, http://www.pcmanet.org/) and Express Scripts (St. Louis, MO, http://www.express-scripts.com/) regarding the cost savings, interchangeability, and market penetration of follow-on biologics.

BIO criticized the studies as legislative debate for establishing a regulatory pathway for approval of follow-on biologics continued. Express Scripts cited savings of $71 billion over 10 years and $3.5 billion in the first year if a regulatory pathway for approving generic biologic-based products is established. The study may be found at http:// http://www.express-scripts.com/ourcompany/news/outcomesresearch/onlinepublications/. The PCMA study also analyzed potential cost savings and can be found at http:// http://www.pcmanet.org/newsroom/2007/Documents/EN%20Paper%20on%20Follow-on%20Biologics%20Jan.%202007.pdf.

"As a result of numerous flawed assumptions and the lack of any credible evidence to support these alleged savings, we believe these studies should be rejected as unscientific and unreliable," said BIO President and CEO Jim Greenwood in a prepared statement.

"This debate should be focused on and driven by credible science, fact-based studies, and patient safety," he continued. "These studies fail to meet these standards. They cannot be relied on in lieu of a more rigorous analysis. Congress should recognize these flaws and misleading assumptions and reject these studies as it evaluates proposals regarding follow-on biologics."

Among its criticisms, BIO said that assumptions of interchangeability of biologics were faulty and resulted in overestimates of potential cost savings. The BIO study pointed out that the US Food and Drug Administration (Rockville, MD, http://www.fda.gov/) has not yet determined how interchangeability can be established for complex proteins.

BIO also criticized the PCMA study for overestimating the market penetration of follow-on products. "The PCMA study assumes that for every biologic that comes off patent, there will be an associated follow-on product," said BIO. "There is no credible evidence to suggest that it is scientifically possible to develop a follow-on for every biologic that is currently on the market. Further, many biologics have a limited market, and therefore, it likely will be economically less attractive for companies to pursue manufacturing of follow-ons for many of these products."

BIO's full response to the studies may be found at http:// http://www.bio.org/healthcare/followon/20070222.pdf.
-Patricia Van Arnum


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here